OncoSil Medical Ltd股票討論區

OncoSil Medical (ASX:OSL) reveals results of a study showing that the addition of OncoSil™ to systemic chemotherapy significantly increases the vascularity of the primary pancreatic tumors and at the same time results in a significant decrease in the size of the tumours.
- This is believed to be the first study in humans demonstrating that the poor vascularity of pancreatic cancer tumors can be increased
- This may consequently increase the concentration of chemotherapy agents within the tumor ...